Evidence map›Paper›PMID 37887540›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.

Markus Falk, Stefanie Schatz, Fabian P M Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brueckl

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Markus FalkInstitute for Hematopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.ORCID 0000-0001-5511-9146
Stefanie SchatzInstitute for Hematopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.ORCID 0000-0003-2811-3667
Fabian P M ReichDepartment of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuremberg, Ernst-Nathan-Str. 1, 90419 Nuremberg, Germany.
Stefanie SchmidtInstitute for Hematopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Marco GalsterDepartment of Radiology, Paracelsus Medical University, General Hospital Nuremberg, Ernst-Nathan-Str. 1, 90419 Nuremberg, Germany.
Markus TiemannInstitute for Hematopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Joachim H FickerDepartment of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuremberg, Ernst-Nathan-Str. 1, 90419 Nuremberg, Germany.ORCID 0000-0002-7175-5852
Wolfgang M BruecklDepartment of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuremberg, Ernst-Nathan-Str. 1, 90419 Nuremberg, Germany.ORCID 0000-0002-7039-0791
Institut für Hämatopathologie Hamburg · DENuremberg Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesAniline CompoundsErbB ReceptorsFemaleHumansIndolesMutationProtein Kinase InhibitorsPyrimidinesAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesdisease monitoringEGFRhybrid capture NGSliquid biopsyosimertinib

Identifiers

PMID37887540
PMCPMC10605132
OpenAlexW4387132514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.